AbCellera Biologics (NASDAQ: ABCL)
AbCellera Biologics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AbCellera Biologics Company Info
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
News & Analysis
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say this drug developer can more than double your money.
3 Growth Stocks That Could Go Parabolic in 2024
These innovation-oriented companies could take flight this year.
How to Invest Like Peter Thiel
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
These companies are leading the way in using AI in healthcare.
Why AbCellera Biologics Rallied as Much as 24% on Wednesday
The contract drug developer's stock is finally shaking off the froth of its initial public offering.
Why AbCellera Biologics Is 10% Lower Today
The company has a plan for life after COVID-19, though it pales in comparison.
Why AbCellera Biologics Stock Sank 21.6% in October
The biotech is now down roughly 56% across 2021's trading.
Valuation
Earnings Transcripts
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript
ABCL earnings call for the period ending December 31, 2024.
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2024.
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
ABCL earnings call for the period ending June 30, 2024.
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.